CPRX
Catalyst Pharmaceuticals Inc
31.50$
+0.0%
vs. previous close
Closing price · As of: Jul 21, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +3.1% | +7.7% | -10.9% | +24.6% | +4.9% | +10.2% | -0.3% | +3.6% | +1.2% | +2.8% | -2.1% | – | |
| – | +17.6% | +11.6% | -20.8% | +23.0% | +25.1% | +12.3% | -17.2% | +67.3% | -15.5% | +3.0% | -7.3% | – | |
| – | +1.1% | +7.0% | -9.3% | +24.8% | +2.0% | +9.8% | +2.8% | -5.6% | +5.6% | +2.8% | -1.0% | – | |
| – | +2,015.9% | -97.6% | +30.9% | +15.7% | +10.0% | +15.7% | +2.3% | +12.1% | -39.0% | -32.0% | +47.3% | – | |
| – | +17.8% | +10.3% | +65.0% | -33.0% | +199.5% | -68.8% | +227.7% | -4.7% | +5.5% | -55.5% | +148.8% | – | |
| – | +207.8% | -57.8% | +10.9% | -9.9% | +10.3% | -2.0% | +4.9% | -16.4% | +12.9% | +13.9% | -19.7% | – | |
| – | -179.6% | – | -34.9% | +100.0% | -6.2% | +23.4% | +0.8% | +4.6% | 0.0% | -6.7% | +18.4% | – | |
| – | – | +543.0% | – | – | – | – | – | – | – | – | – | – | |
| – | -178.4% | – | -37.7% | +91.8% | +2.5% | +29.7% | -3.9% | -2.8% | +2.5% | +1.2% | +17.1% | – | |
| – | -167.5% | – | -51.0% | +157.9% | -11.2% | +37.0% | -20.3% | +18.1% | +6.2% | +5.2% | +6.7% | – | |
| – | -181.5% | – | -33.2% | +75.3% | +7.6% | +27.5% | +1.4% | -8.2% | +1.3% | -0.2% | +20.9% | – | |
| – | -151.1% | – | -31.0% | +69.3% | +2.2% | +25.5% | -3.5% | -2.5% | +2.2% | +1.2% | +15.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.